BEGIN:VCALENDAR
VERSION:2.0
METHOD:PUBLISH
CALSCALE:GREGORIAN
PRODID:-//WordPress - MECv7.32.0//EN
X-ORIGINAL-URL:https://directorsforum.com/
X-WR-CALNAME:Corporate Directors Forum
X-WR-CALDESC:Helping directors, and those who support them, build more effective boards.
X-WR-TIMEZONE:America/Los_Angeles
BEGIN:VTIMEZONE
TZID:America/Los_Angeles
X-LIC-LOCATION:America/Los_Angeles
BEGIN:DAYLIGHT
TZOFFSETFROM:-0800
TZOFFSETTO:-0700
TZNAME:PDT
DTSTART:20260308T030000
RRULE:FREQ=YEARLY;BYMONTH=03;BYDAY=2SU
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0700
TZOFFSETTO:-0800
TZNAME:PST
DTSTART:20261101T010000
RRULE:FREQ=YEARLY;BYMONTH=11;BYDAY=1SU
END:STANDARD
END:VTIMEZONE
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-PUBLISHED-TTL:PT1H
X-MS-OLK-FORCEINSPECTOROPEN:TRUE
BEGIN:VEVENT
CLASS:PUBLIC
UID:MEC-e7532dbeff7ef901f2e70daacb3f452d@directorsforum.com
DTSTART;TZID=America/Los_Angeles:20220614T130000
DTEND;TZID=America/Los_Angeles:20220614T150000
DTSTAMP:20231213T003735Z
CREATED:20231213
LAST-MODIFIED:20231213
PRIORITY:5
SEQUENCE:1
TRANSP:OPAQUE
SUMMARY:Navigating Investor Expectations in a Time of Geopolitical Risk
DESCRIPTION:BROUGHT TO YOU IN PARTNERSHIP WITH NIRI & NASDAQ\nGlobal geopolitical dynamics have a consistent impact on financial markets.  Directors and executives operate in markets that underpin supply chains, financing, capital markets and M&A among other critical areas.\nOur experts will discuss:\n\nMarket-moving risks that companies should keep on their radar\nConsiderations for allocation of capital focused on long-term growth\nKey areas driving today’s most significant risks (i.e., international conflicts, cybersecurity, terrorism)\nCommunication strategies with stakeholders to position for enhanced opportunities\n\nClick below to learn more about our speakers!\n\n\n\n\n\n\n\n\n\nLead Independent Director, Histogen, Inc.; Chairman, Phoenix Molecular Designs; Independent Director, Paracrine Inc.; Director, California Life Sciences; Chair of Capital Development and Board of Governors, BIOCOM California; Managing General Partner, Equitos Venture Partners LLC\nDavid H. Crean\n\n\n\n\n\nVice President, Investor Relations, NuVasive, Inc.\nJuliet Cunningham\n\n\n\n\n\nSenior Managing Director, Equity, Derivatives, and Quantitative Strategy Team, Evercore ISI\nJulian Emanuel\n\n\n\n\n\n\n\n\n\n\nLead Independent Director, Histogen, Inc.; Chairman, Phoenix Molecular Designs; Independent Director, Paracrine Inc.; Director, California Life Sciences; Chair of Capital Development and Board of Governors, BIOCOM California; Managing General Partner, Equitos Venture Partners LLC\nDavid H. Crean\nDavid has +25 years buy- and sell-side expertise of M&A, partnering and investments within the life sciences and healthcare sectors working within strategic biopharmaceutical companies, private equity, investment banking and venture capital. He is the Managing General Partner of Equitos Venture Partners LLC, an emerging life sciences-focused investment fund. In parallel to Equitos, he is a limited partner for Suncoast Ventures and Mesa Verde Venture Partners, two life sciences venture funds focused on incubator through growth-stage companies. Aside from his investment activities, he also serves as Managing General Partner for Cardiff Advisory LLC, a boutique mergers & acquisitions investment banking and strategic advisory firm focused on M&A for life sciences and healthcare companies. Through his Cardiff Advisory affiliation, he serves in fractional CEO and CBO roles for a few private and public companies.\nDavid currently serves in leading Boards of Director roles for Histogen, Inc. (Nasdaq: HSTO) as Lead Independent Director, Phoenix Molecular Designs as Board Chairman, Independent Board Member for Paracrine Inc., on the Executive Committee and Board for California Life Sciences (CLS), and BIOCOM California’s Board of Governors as Chair of Capital Development. David is an active member of the Association for Corporate Growth (ACG) and served as President for the past two years of the San Diego, CA chapter, is active member of CEO’s Against Cancer for the American Cancer Society, and serves as Chairman of the Board for the Alzheimer’s Association for San Diego/ Imperial Counties.\nDavid holds FINRA Series 79 and Series 63 licenses and is a Registered Investment Banking Representative of BA Securities LLC, Member FINRA SIPC. He holds a Doctorate of Philosophy (Ph.D.) Degree in Biophysics and a Masters of Science (MS) Degree in Oncology from the State University of New York at Buffalo. He earned a Bachelor of Science (BS) Degree in Biology/ Pre-Med from Canisius College. Additionally, he holds a Masters of Business Administration (MBA) Degree with a finance concentration from Pepperdine University Graziadio School of Management.\n\n\n\n\n\n\n\n\n\n\n\nVice President, Investor Relations, NuVasive, Inc.\nJuliet Cunningham\nJuliet Cunningham has been an investor relations professional for 25 years. She draws from a diverse background including corporate, financial, media and regulatory communications. Ms. Cunningham has served in senior IR and communications roles in healthcare (NuVasive, Nevro and Alere) and technology sectors (Qualcomm, Novatel Wireless and Linkabit Corp). In addition, she has consulted with companies ranging from start-ups to Fortune 500 in wireless technology, healthcare, and biotech. Ms. Cunningham has taken companies public, supported small and large M&A transactions, and has guided management teams through periods of transformative change. Juliet Cunningham holds a bachelor’s degree in business administration, and completed graduate programs in investor relations and executive leadership at the University of Michigan and Stanford University, respectively.\n\n\n\n\n\n\n\n\n\n\n\nSenior Managing Director, Equity, Derivatives, and Quantitative Strategy Team, Evercore ISI\nJulian Emanuel\nJulian Emanuel is a Senior Managing Director leading the Equity, Derivatives, and Quantitative Strategy team at Evercore ISI.\nMr. Emanuel was Chief Equity and Derivatives Strategist at BTIG for the past four years with supplemental responsibility for Alternative Assets and Cryptocurrency Strategy. Prior roles include Chief U.S. Equity and Derivatives Strategist at UBS, as well as Portfolio Management responsibilities at Tiedemann Investment Group, Goldman Sachs/SLK, and Credit Suisse Asset Management. His unique background includes tenure as an Index and Single Stock options market maker on the American Stock Exchange and as Head of the Equity Derivatives sales desk at Tullett Prebon.\nMr. Emanuel holds an MBA in Finance from NYU’s Stern School of Business and a BBA from Emory University.\n\n\n\n\n\n \n\nAGENDA:\n1:00 pm to 1:35 pm Networking\n1:35 pm to 3:00 pm Lunch & Program\nCOST\nCDF Members: FREE\nCorporate Members: FREE (4)\nFCD Members: FREE\nNon-Members: $75\nACCREDITATION:\nAll participants may receive 1 hour of MCLE and CPE education credit. Click here ( https://directorsforum.com/programs-and-events/continuing-ed-credits/ ) for more details\nRegister Below!\nIndividual Members\nFCD Members\nCorporate & Strategic Partner Members\nNon-Members\n \n
URL:https://directorsforum.com/event/navigating-investor-expectations-in-a-time-of-geopolitical-risk/
CATEGORIES:Special Lunch Program
LOCATION:3777 La Jolla Village Dr, San Diego, CA 92122
ATTACH;FMTTYPE=image/jpeg:https://directorsforum.com/wp-content/uploads/2023/12/Featured-Image-811x415-1.jpg
END:VEVENT
END:VCALENDAR